TRV027: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−54%

Mortality (2)−54%

RCTs (2)−54%

RCT mortality (2)−54%

Late (2)−54%

00.511.5+

← TRV027
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

TRV027 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.99death2/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08death145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.992/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.99death2/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08death145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Self (DB RCT)−35%1.35 · 0.89–2.08no recov.145 (n)145 (n)ACTIV-4

Late treatment−35%1.35 · 0.88–2.07145 (n)145 (n)35% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.17

All studies−35%1.35 · 0.88–2.07145 (n)145 (n)35% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1700.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.99death2/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08death145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.992/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.99death2/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08death145 (n)145 (n)ACTIV-4

Late treatment−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.21

All studies−54%1.54 · 0.78–3.022/1601/15854% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2100.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →

c19early.org

October 2026

TRV027 COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Robbins (DB RCT)−73%1.73 · 0.18–16.99death2/151/13COVRAS Self (DB RCT)−52%1.52 · 0.75–3.08death145 (n)145 (n)ACTIV-4 Self (DB RCT)−35%1.35 · 0.89–2.08no recov.145 (n)145 (n)ACTIV-4

00.511.52+

Rotate screen for more detailsIncrease width for more details

← TRV027
reduces riskTRV027
increases risk →